UNSPSC 51384701: Cinnopentazone or cintazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C22H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0BI682BR2D, chemically known as 2-pentyl-6-phenyl-1h-pyrazolo(1,2-a)quinoline-1,3-(2h)-dione but generally known as cinnopentazone, which bears US NIH Compound Identifier 16347. European Medicines Agency schedules Cinnopentazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06305MIG.

UNSPSC 51384701 Cinnopentazone or cintazone is a Commodity code, but recent state and local procurement activity under this code shows minimal alignment with the nominal chemical classification. The three most recent opportunities posted under this code span pharmaceutical and health-system procurement broadly — naloxone (an opioid antagonist) and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. None of these solicitations specifically reference cinnopentazone or cintazone by name. State and local buyers posting under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP).

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 — note the date anomaly in the source record. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. The code shows significant taxonomic misalignment with recent posted opportunities, suggesting either inconsistent code assignment by issuing bodies or minimal current procurement demand for the specific chemical product named in the code.